NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Erythrocyte encapsulated asparaginase for treating acute lymphoblastic leukaemia [ID864]

Matrix of consultees and commentators

| Consultees Commentators (no right to submit or | |
|---|---|
| Consuitees | Commentators (no right to submit or appeal) |
| | appeary |
| Company | General |
| Orphan Europe (Erythrocyte | Allied Health Professionals Federation |
| encapsulated asparaginase) | Board of Community Health Councils in |
| orroapoulated doparaginace) | Wales |
| Patient/carer groups | British National Formulary |
| Action for Sick Children | Care Quality Commission |
| African Caribbean Leukaemia Trus | |
| (ACLT) | and Public Safety for Northern Ireland |
| Anthony Nolan | Healthcare Improvement Scotland |
| Black Health Agency | Medicines and Healthcare products |
| Bloodwise | Regulatory Agency |
| Cancer Black Care | National Association of Primary Care |
| Cancer Equality | National Pharmacy Association |
| Cancer52 | NHS Alliance |
| Childhood Cancer Parents Alliance | NHS Blood and Transplant |
| Children with Cancer UK | NHS Commercial Medicines Unit |
| Children's Cancer & Leukaemia | NHS Confederation |
| Group | Scottish Medicines Consortium |
| CLIC Sargent | |
| Delete Blood Cancer | Comparator companies |
| Equalities National Council | Shire Pharmaceuticals (pegylated |
| • HAWC | asparaginase) |
| Helen Rollason Cancer Charity | Jazz Pharmaceuticals (Erwinia-derived) |
| Independent Cancer Patients Voice | |
| Leukaemia Cancer Society | Medac GmbH (E.coli asparaginase) |
| Leukaemia CARE | Delevent recepted groups |
| Macmillan Cancer Support | Relevant research groups |
| Maggie's Centres | Cochrane Haematological Malignancies Group |
| Marie Curie Cancer Care | Institute of Cancer Research |
| Muslim Council of Britain | Leuka |
| National Children's Bureau | Leuka Leukaemia Busters |
| Rarer Cancers Foundation | MRC Clinical Trials Unit |
| South Asian Health Foundation | National Consen Descenda Institute |
| Specialised Healthcare Alliance | National Cancer Research Institute |

National Institute for Health and Care Excellence

Matrix for technology appraisal of erythrocyte encapsulated asparaginase for treating acute lymphoblastic leukaemia [ID864]

Issue date: August 2016

| Consultees | Commentators (no right to submit or appeal) |
|--|---|
| Teenage Cancer Trust Tenovus Cancer Care Together for Shorter Lives | National Cancer Research Network National Institute for Health Research |
| Professional groups Association of Cancer Physicians British Committee for Standards in Haematology British Geriatrics Society British Institute of Radiology British Psychosocial Oncology Society British Society for Haematology Cancer Research UK Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiograpers UK Clinical Pharmacy Association UK Health Forum UK Oncology Nursing Society | Associated Public Health Groups Public Health England Public Health Wales |
| Others Department of Health NHS England NHS Cumbria CCG NHS Redditch and Bromsgrove CCG Welsh Government | |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*.

All non-company commentators are invited to nominate clinical specialists or patient experts.

National Institute for Health and Care Excellence Matrix for technology appraisal of erythrocyte encapsulated asparaginase for treating acute lymphoblastic leukaemia [ID864] Issue date: August 2016

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.